Format

Send to

Choose Destination
Metabolomics. 2016;12:15. doi: 10.1007/s11306-015-0877-5. Epub 2015 Nov 18.

Global metabolomics reveals metabolic dysregulation in ischemic retinopathy.

Author information

1
Department of Cell and Molecular Biology, The Scripps Research Institute, MB 28, 10550 North Torrey Pines Road, La Jolla, CA 92037 USA.
2
Scripps Center for Metabolomics and Mass Spectrometry, The Scripps Research Institute, 10550 North Torrey Pines Road, La Jolla, CA 92037 USA.
3
Department of Ophthalmology, Tokyo Medical University, 6-7-1 Nishishinjuku, Shinjuku-ku, Tokyo, 160-0023 Japan.
4
Departments of Chemistry, Genetics, and Medicine, Washington University School of Medicine, St. Louis, MO 63110 USA.
5
The Lowy Medical Research Institute, 3030 N. Torrey Pines Court, La Jolla, CA 92037 USA.
#
Contributed equally

Abstract

Proliferative diabetic retinopathy (PDR) is the most severe form of diabetic retinopathy and, along with diabetic macular edema, is responsible for the majority of blindness in adults below the age of 65. Therapeutic strategies for PDR are ineffective at curtailing disease progression in all cases; however a deeper understanding of the ocular metabolic landscape in PDR through metabolomic analysis may offer new therapeutic targets. Here, global and targeted mass spectrometry-based metabolomics were used to investigate metabolism. Initial analyses on vitreous humor from patients with PDR (n = 9) and non-diabetic controls (n = 11) revealed an increase of arginine and acylcarnitine metabolism in PDR. The oxygen-induced-retinopathy (OIR) mouse model, which exhibits comparable pathological manifestations to human PDR, revealed similar increases of arginine and other metabolites in the urea cycle, as well as downregulation of purine metabolism. We validated our findings by targeted multiple reaction monitoring and through the analysis of a second set of patient samples [PDR (n = 11) and non-diabetic controls (n = 20)]. These results confirmed a predominant and consistent increase in proline in both the OIR mouse model and vitreous samples from patients with PDR, suggesting that over activity in the arginine-to-proline pathway could be used as a therapeutic target in diabetic retinopathy.

KEYWORDS:

Arginine metabolism; Pathway enrichment analysis; Proliferative diabetic retinopathy; Untargeted metabolomics

Supplemental Content

Full text links

Icon for PubMed Central
Loading ...
Support Center